【Health and Welfare News】 AstraZeneca Korea (CEO and President Jeon Se-hwan, hereinafter referred to as AZ)’s ‘Tagriso (ingredient name: osimertinib)’ has expanded insurance coverage as a first-line treatment for EGFR-mutated non-small cell lung cancer. This is the first time in five years that an application for expansion of primary treatment benefits has been made.
The Ministry of Health and Welfare recently announced partial revisions to the ‘Details on Application Standards and Methods of Nursing Care Benefits’.
According to this, Tagrisso will be covered as the first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletion (Ex19del) or exon 21 (L858R) substitution mutation starting January 1 of this year. This is an achievement 60 months after applying for expanded coverage as a first-line treatment in January 2019.
Tagrisso is the first third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which was first used as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletion or exon 21 substitution mutation in 2018. Approved domestically in March
Since its launch, Tagrisso has been used in more than 700,000 EGFR-mutated non-small cell lung cancer patients worldwide. There are 66 countries around the world where it is covered as a first-line treatment.
Professor Ahn Myeong-ju of the Department of Oncology at Samsung Seoul Hospital (Chairman of the Korean Lung Cancer Society) said, “There has been a very high demand from clinical sites and patients for the first-line treatment coverage of Tagrisso,” and added, “The 1st treatment of Tagrisso, which was the most urgent issue in domestic lung cancer treatment, “We welcome the expansion of tea treatment benefits,” he said.
Yang Mi-seon, Executive Director of AZ Oncology Business Division, said, “We would like to thank everyone once again who have worked hard to get Tagrisso covered over the past five years since Tagrisso was approved as a first-line treatment in Korea in 2018.” She added, “Tagriso is a treatment for patients with EGFR mutations. “As the global standard of care for non-small cell lung cancer, we will continue to challenge and strive to improve the survival rate of lung cancer patients.”
Meanwhile, insurance coverage for Tagrisso’s competitor, Yuhan Corporation’s Lecraza, was expanded to allow for primary lung cancer treatment starting the same day. The expansion of Lekraza’s first benefit occurred about five months after application.
2024-01-02 03:11:00
#Health #Welfare #News #Tagrisso #applies #benefits #lung #cancer #primary #treatment #years #launch
